End-of-day quote
Korea S.E.
23:00:00 12/05/2024 BST
|
5-day change
|
1st Jan Change
|
4,665
KRW
|
-1.79%
|
|
-0.85%
|
-11.65%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
61,527
|
66,725
|
108,199
|
130,082
|
102,750
|
85,445
|
Enterprise Value (EV)
1 |
61,225
|
66,821
|
107,646
|
118,985
|
111,249
|
92,497
|
P/E ratio
|
18.7
x
|
15.1
x
|
90.7
x
|
-49.7
x
|
-16.4
x
|
-11.9
x
|
Yield
|
1.9%
|
1.85%
|
1.44%
|
1.34%
|
1.69%
|
-
|
Capitalization / Revenue
|
0.74
x
|
0.73
x
|
1.1
x
|
1.12
x
|
0.74
x
|
0.62
x
|
EV / Revenue
|
0.74
x
|
0.74
x
|
1.1
x
|
1.03
x
|
0.8
x
|
0.67
x
|
EV / EBITDA
|
8.21
x
|
5.97
x
|
10.6
x
|
20.9
x
|
25.1
x
|
19
x
|
EV / FCF
|
-11.1
x
|
13.7
x
|
-5.88
x
|
-88.1
x
|
-9.14
x
|
-12.3
x
|
FCF Yield
|
-8.99%
|
7.3%
|
-17%
|
-1.14%
|
-10.9%
|
-8.14%
|
Price to Book
|
0.73
x
|
0.76
x
|
0.96
x
|
1.07
x
|
0.89
x
|
0.78
x
|
Nbr of stocks (in thousands)
|
11,719
|
11,758
|
14,822
|
16,656
|
16,519
|
16,183
|
Reference price
2 |
5,250
|
5,675
|
7,300
|
7,810
|
6,220
|
5,280
|
Announcement Date
|
20/03/19
|
18/03/20
|
17/03/21
|
23/03/22
|
22/03/23
|
20/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
83,096
|
90,878
|
98,120
|
115,655
|
138,881
|
137,210
|
EBITDA
1 |
7,455
|
11,195
|
10,170
|
5,703
|
4,435
|
4,858
|
EBIT
1 |
5,328
|
8,075
|
6,271
|
1,200
|
-592.1
|
-748.9
|
Operating Margin
|
6.41%
|
8.89%
|
6.39%
|
1.04%
|
-0.43%
|
-0.55%
|
Earnings before Tax (EBT)
1 |
4,648
|
6,600
|
3,711
|
-383.2
|
-3,810
|
-5,442
|
Net income
1 |
4,020
|
4,722
|
1,284
|
-2,214
|
-5,988
|
-7,181
|
Net margin
|
4.84%
|
5.2%
|
1.31%
|
-1.91%
|
-4.31%
|
-5.23%
|
EPS
2 |
281.5
|
376.3
|
80.44
|
-157.0
|
-378.3
|
-443.0
|
Free Cash Flow
1 |
-5,505
|
4,880
|
-18,305
|
-1,351
|
-12,176
|
-7,527
|
FCF margin
|
-6.63%
|
5.37%
|
-18.66%
|
-1.17%
|
-8.77%
|
-5.49%
|
FCF Conversion (EBITDA)
|
-
|
43.59%
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
103.34%
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
100.0
|
105.0
|
105.0
|
105.0
|
105.0
|
-
|
Announcement Date
|
20/03/19
|
18/03/20
|
17/03/21
|
23/03/22
|
22/03/23
|
20/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
96.3
|
-
|
-
|
8,499
|
7,053
|
Net Cash position
1 |
302
|
-
|
553
|
11,097
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
0.008604
x
|
-
|
-
|
1.916
x
|
1.452
x
|
Free Cash Flow
1 |
-5,505
|
4,880
|
-18,305
|
-1,351
|
-12,176
|
-7,527
|
ROE (net income / shareholders' equity)
|
5.08%
|
6.27%
|
2.32%
|
-0.75%
|
-3.51%
|
-4.55%
|
ROA (Net income/ Total Assets)
|
2.59%
|
3.7%
|
2.68%
|
0.43%
|
-0.19%
|
-0.24%
|
Assets
1 |
154,978
|
127,702
|
47,916
|
-513,404
|
3,141,489
|
3,018,454
|
Book Value Per Share
2 |
7,210
|
7,433
|
7,579
|
7,306
|
6,986
|
6,772
|
Cash Flow per Share
2 |
2,301
|
2,283
|
1,362
|
3,018
|
1,580
|
1,891
|
Capex
1 |
9,763
|
8,056
|
12,047
|
6,073
|
5,283
|
4,514
|
Capex / Sales
|
11.75%
|
8.87%
|
12.28%
|
5.25%
|
3.8%
|
3.29%
|
Announcement Date
|
20/03/19
|
18/03/20
|
17/03/21
|
23/03/22
|
22/03/23
|
20/03/24
|
|
1st Jan change
|
Capi.
|
---|
| -11.65% | 56.12M | | +7.22% | 72.81B | | +12.72% | 9.13B | | -11.75% | 5.13B | | +59.61% | 4.99B | | +2.62% | 3.9B | | -17.54% | 2.48B | | +21.35% | 2.42B | | -27.82% | 2.32B | | +25.13% | 2.17B |
Specialty & Advanced Pharmaceuticals
|